Value Proposition AAV has become one of the leading gene delivery vectors in clinical development. Gene therapy using recombinant AAV has been demonstrated to be safe and well-tolerated in virtually every clinical setting in which it has been used. To date nearly 100 clinical trials are testing the safety and efficacy of AAV based…

Read More